Analyst Price Targets — DXCM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 2:17 pm | — | Robert W. Baird | $87.00 | $70.67 | TheFly | DexCom price target raised to $87 from $82 at Baird |
| February 13, 2026 12:40 pm | Anthony Petrone | Mizuho Securities | $90.00 | $65.08 | TheFly | DexCom price target raised to $90 from $78 at Mizuho |
| February 13, 2026 11:56 am | — | Canaccord Genuity | $95.00 | $65.08 | TheFly | DexCom price target lowered to $95 from $99 at Canaccord |
| February 13, 2026 11:14 am | — | Barclays | $72.00 | $65.08 | TheFly | DexCom price target raised to $72 from $71 at Barclays |
| January 12, 2026 1:46 pm | — | Barclays | $71.00 | $69.67 | TheFly | Barclays downgrades DexCom to Underweight on rising competition |
| January 9, 2026 11:48 am | — | Bernstein | $86.00 | $68.43 | TheFly | DexCom price target raised to $86 from $84 at Bernstein |
| December 17, 2025 11:56 am | — | Mizuho Securities | $78.00 | $66.37 | TheFly | DexCom price target raised to $78 from $75 at Mizuho |
| December 16, 2025 11:19 am | Mike Kratky | Leerink Partners | $92.00 | $65.38 | StreetInsider | DexCom (DXCM) PT Raised to $92 at Leerink Partners |
| December 2, 2025 11:18 am | Patrick Wood | Morgan Stanley | $75.00 | $63.52 | TheFly | DexCom upgraded to Overweight from Equal Weight at Morgan Stanley |
| November 10, 2025 5:14 pm | — | Morgan Stanley | $63.00 | $55.21 | TheFly | DexCom price target lowered to $63 from $89 at Morgan Stanley |
Latest News for DXCM
111 Capital grew its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 62.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,004 shares of the medical device company's stock after purchasing an additional 10,040 shares during the quarter. 111
Andra AP fonden raised its position in DexCom, Inc. (NASDAQ: DXCM) by 30,833.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 92,800 shares of the medical device company's stock after buying an additional 92,500 shares during the period.
DNB Asset Management AS raised its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 271.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,098,544 shares of the medical device company's stock after acquiring an additional 803,086 shares during the quarter.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Rick Osterloh to Board of Directors.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.